Background
TPE is a continuous extracorporeal process during which plasma and cellular components of whole blood (taken from the patient's vein) are directed into the TPE machine and are separated predominantly by one of two methods. 1 The first method uses centrifugal force with whole blood entering a rapidly revolving bowl, allowing blood to be separated by density into plasma, platelet, leukocyte, and RBC layers; the TPE device has a proprietary interface that allows selective extraction of any of these layers. The second method uses the property of size, called membrane filtration. These latter TPE instruments contain a microporous filter that allows plasma to pass through, separating plasma from cellular components. Regardless of method, once the desired component is separated, the remaining blood may be returned to the patient with or without replacement fluids. While TPE is an effective form of therapy for selected conditions, it does not achieve 100% removal of a target. The mixture of replacement fluid with plasma results in dilution and, ultimately, diminished removal efficiency with each exchange. Typically, one plasma volume exchange removes approximately 63% of plasma contents, 1.5 plasma volume exchange removes around 78%, and two volume exchange removes approximately 86%. 2 In addition to depleting potentially pathologic agents in peripheral blood, it is important to consider that the process of TPE may have profound, unanticipated effects on other circulating elements. In particular, TPE has been recognized to have a potential impact on blood levels of therapeutic drugs. 3 However, not all drugs are equivalent with regard to their removal by TPE, and there remains confusion and uncertainty about the effects of plasma exchange on the circulating levels of many medications. In fact, a review of the existing literature of TPE effects on drug levels revealed significant methodologic flaws 4 and an absence of randomized controlled trials (RCTs). 4 This leads to conflicting conclusions on the clinical effects, utility, and contraindications to TPE for patients on concurrent drug therapy. As such, the primary goal of this review article is to examine and summarize the current literature on the effects of TPE on medication levels. We will examine both procedure-specific as well as clinical/pharmacologic drug properties to better demonstrate how these factors interact and influence the effects of TPE on drug levels. We also will detail clinical applications for TPE in moderating drug levels. Finally, we will outline future directions for investigation.
Methods for This Review
Both the Cochrane Database and PubMed-MEDLINE (1996 to August 2016) were searched for all case reports, case series, and human RCTs related to TPE-associated medication removal. Search keywords included but were not limited to: plasmapheresis, therapeutic plasma exchange, drug removal, medication levels, drug serum level, drug plasma level, and pharmacokinetics. The articles were reviewed for proposed mechanisms and factors influencing TPE effect on circulating medication levels. Approximately 60 peer-reviewed articles were identified with the majority being case reports related to accidental and intentional medication overdoses. No RCTs were identified.
Physiology and Pharmacokinetics of Drug Removal by TPE
Historically, the TPE medication literature has emphasized two key pharmacokinetic (PK) drug-dependent factors important in determining the effect of TPE on the maintenance of therapeutic drug levels. Typically, drugs with high plasma protein binding affinity (>80%) and low volumes of distribution (V D <0.2 L/kg) remain largely in the intravascular compartment and are thus most vulnerable to influences from plasma exchange. 5 However, several additional clinical and drug-related factors influence, interact with, and mitigate the potential effect of TPE on drug levels. These factors are summarized in ❚Table 1❚, and we will discuss some of the mechanisms underlying each of these factors.
First, while PK characteristics such as low V D and high plasma protein binding affinity allow drugs to remain in the intravascular compartment and accessible to TPE for removal, 6, 7 it is important to note that V D and protein binding are not uniform in every patient and can
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Cheng et al / TPE EffEcTs on Drug LEvELs be dependent on factors such as drug dose, endogenous clearance rates, and nutritional status. 8, 9 Second, many drugs such as cisplatin, 10 gentamycin, vancomycin, phenytoin, and carbamazapene 8 show multicompartmental kinetics, meaning they bind with differing affinities in differing compartments and redistribute at varying rates. This can lead to varying effects of TPE on drug levels based on timing of treatment, the duration and frequency of treatment, and the timing of drug-level measurements relative to the procedure. For instance, mid-TPE or immediately post-TPE, drug-level measurements may underestimate or overestimate the removal of medications and not account for redistribution effects on therapeutic levels. 11, 12 Yet another factor that many studies fail to account for is the effect of concurrent endogenous clearance when attributing changes in drug levels to TPE. 13 Drugs that rapidly clear, such as those with short half-lives 14 or those that are rapidly metabolized and endogenously cleared with normal or improving organ function, 15 may be minimally affected by TPE. Studies suggest that TPE may have only a clinically significant impact on drug levels if it increases total drug clearance by 30% 16 or when endogenous clearance is less than 4 mL/min (in cases of acute kidney injury or other organ dysfunction) 17 and drug half-life is longer than 2 hours, the approximate duration of most TPE procedures. 18 It is also important to note that intravascular drug concentrations significantly affect the efficiency by which TPE will influence drug levels; therefore, the time between the drug dose and initiation of TPE is a major factor influencing drug removal. 19 Medications with high or low V D , if given enough time, may distribute to extravascular spaces and thus be increasingly unaffected by TPE. 19 Variation across case reports in the timing of TPE initiation in relation to drug dose may contribute to conflicting results on the effect of TPE even when looking at the same drug. 20 In addition, in overdose situations where binding proteins and endogenous clearance pathways are overwhelmed resulting in altered normal PK parameters (eg, V D ), 21 the intravascular drug concentrations may be changed in unpredictable ways, contributing to conflicting results in the literature. Some correlation between serum drug level and biological effect must also exist, or else the effect of TPE on drug levels is clinically immaterial. This includes some β-blockers 22 and new monoclonal drug classes 23 where the medication acts on specific tissues; therefore, serum concentration of the drug has a minimal association with its clinical effect. High binding affinity and specificity of monoclonal biological agents such as natalizumaub for leukocyte proteins, however, may be exploited and allow for TPE treatments in the event of overdose causing immunosuppression. 24 While it is important to note that drug molecular weight and protein-bound size can be a major limitation for hemodialysis to influence drug levels, these are less of a barrier in TPE, which removes drugs independent of size, charge, or lipid binding properties. 25 TPE, however, is less efficient in removing small nonprotein-bound molecules or uremic toxins or correcting drug-related metabolic derangements of electrolytes, and in those situations, hemodialysis treatment may be clinically useful. 18 The choice of replacement fluid can also have a clinical effect on drug levels and free fractions of circulating medications. 6 In a case of drug overdose, the American Society for Apheresis (ASFA) guidelines suggest the use of albumin or fresh-frozen plasma (FFP) based on the specific drug-binding affinities to help draw the medication into the intravascular space. 26 Albumin is responsible for most nonspecific protein binding of drugs, and theoretically, removal of plasma without albumin replacement could increase the free fraction of drugs after redistribution, leading to worsening clinical toxicity. 18 Use of FFP may be beneficial in situations of overdose with high α1-acid glycoprotein affinity drugs, such as quinidine. 27 Finally, we must acknowledge the multitude of indirect physiologic effects from TPE removal of substances that can cause clinical effects in patients without directly altering medication levels. 8 Removal of coagulation factors can influence the bleeding risk of heparin overdose 28 and direct thrombin inhibitors. 29 Removal of T4/T3 moderates the thyrotoxicosis effects of amiodarone. 30 Removal of autoantibodies can also prolong the actions of some drugs such as anticholinesterase medications. 21 Last, removal of the products of hemolysis through TPE can limit the extent of nephrotoxicity in drug reactions 31 to maintain endogenous clearance.
Limitations of Current Literature
A review of the literature shows the majority of articles investigating the impact of TPE on drug levels to be case reports or case series with no human RCTs. 32 Many case reports investigating TPE effects on drug levels are often done in conjunction with other treatments (gastric lavage, urinary alkalinization, cardiac pacing, immunoadsorption, and specific antidotes), 33 limiting our ability to draw definitive conclusions as to the specific contribution of TPE on drug levels. Reliability and validity issues arise as many case reports use an inconsistent method with different durations, frequency, initiation time of TPE, and measured different drug concentration end points (eg, serum levels vs drug levels in discarded plasma), leading to conflicting conclusions and noncomparable results. 9 Ibrahim et al 4 suggest using drug levels in the waste plasma as the most reliable end point to calculate TPE influence on drug levels. Many of the case reports also fail to consider altered PK properties of many drugs in overdose situations, making TPE effects on drug levels unpredictable. 18 In fact, most studies lack any drug kinetic data (eg, redistribution time, half-life, endogenous clearance rate) to substantiate TPE effect on drug removal 25 or consider patient-specific nutritional and organ function status when calculating TPE contributions to drug removal. 21 In addition, most studies do not distinguish or account for the indirect clinical impact of TPE removal of target binding proteins, antibodies, coagulation factors, and toxic waste products that cause clinical effects without influencing drug levels. 25, 34 Case reports trying to establish the clinical utility of TPE in the clinical management of drug overdose also often ignore inherent risks and complications associated with the procedure, including hypocalcemia from citrate toxicity, vasovagal and hypotensive reactions, plasma donor exposure risks, bleeding and thrombosis risks, central line placement risks, and increased infection risk from hypogammaglobinemia in the setting of repeat TPE procedures. 34, 35 Finally, the biggest practical difficulty in understanding and being able to predict the influence of TPE on drug levels is the need for extensive and detailed PK knowledge, as closely related drugs in the same class can vary significantly in PK characteristics under various clinical contexts. 12 Moving forward, these data and the growing knowledge base must be continually revised and updated as new therapies are introduced each year.
Plasma Exchange and Drug Levels: The "Evidence" and Practical Guidance
Despite the limitations noted in previous sections of this article, pathologists, transfusion medicine practitioners, and other specialists in apheresis will nonetheless be faced with questions and concerns about drug removal, either during TPE or in response to an overdose to a particular medication. As such, in this section, we will try to practically integrate existing data (both case based and those established more rigorously via formal trials) to provide a framework or guideline on expected variations in drug levels across a wide variety of medication classes, with a particular emphasis on drugs/molecules that we often note are administered to patients who may be undergoing TPE. The findings in this section are also summarized in ❚Table 2❚.
Antibiotics
Acyclovir shows a moderate V D of 0.69 L/kg with low protein binding of 15% and is generally poorly removed by TPE. 12 Tobramycin, gentamycin, and vancomycin show evidence for removal by TPE if initiated quickly and continued for longer periods of treatment to allow for removal of medications as they continue to reequilibrate from tissue back into the intravascular space. 4 Cephalosporins, including cefepime, 19 ceftazidime, 36 and ceftriaxone, 37 largely show poor removal by TPE, particularly if given via intramuscular administration. TPE effectively removed ceftriaxone when initiated within 3 hours of administration. 37 Chloramphenicol data suggest removal by TPE; however, specific patient population and measurements of serum level instead of drug level in discard plasma limit
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Antiepileptics
Phenytoin, valproic acid, phenobarbital, oxcarbazepine, and carbamazepine all show relatively high protein binding, with most ranging from 70% to 90% and moderate to high V D , ranging from 0.6 to 1.9 L/kg. These drugs show poor removal via TPE due to their extensive extravascular tissue distribution, leading to significant postprocedure rebound. 8 Short-term reduction in serum levels, however, may provide some clinical benefit to patients, allowing endogenous removal pathway recovery in overdose situations.
Antihypertensives
Amiodarone is generally not removed by TPE, but clearance of circulating immune complexes can mediate clinical improvement or overdose-related alveolitis and polyarthropathy. 40 Removal of excess plasma proteins (eg, T4/T3 and free T4/T3) can indirectly mitigate the effects of amiodarone-related thyrotoxicosis. 30 Verapamil, 41 amlodipine, 42 and diltiazem 43 all show greater than 90% protein binding, suggesting effective TPE removal; however, measurement of serum levels instead of waste plasma drug levels limits interpretation of case reports. Propranolol shows high affinity binding to α1-acid glycoproteins, suggestive of enhanced TPE removal, particularly with FFP replacement. 22, 44 However, the serum concentrations of other β-blockers, such as metoprolol, do not correlate well with clinical effect. As such, TPE is not considered a firstline therapy in overdose. 22 Digoxin overdose case reports are consistent in showing lack of removal by TPE due to a very large V D (5-8 L/kg) and low protein binding (20%-30%) once the drug is fully distributed to tissue. 6 Rabetoy et al 45 have shown a possible role for TPE treatment in overdose situations if used in conjunction with digoxin immune antigen binding fragments, which not only enhance endogenous renal excretion but also allow for enhanced clearance of immune complexes via TPE.
Endocrine and Hormonal Therapies
Case reports for medications that fall into this category include thyroxine 46 and immunosuppressive steroid hormones such as dexamethasone. 47 These medications tend to have high protein binding and moderate V D , leading to higher tissue distribution and lower intravascular levels. Therefore, and primarily based on the significant tissue distribution, medications in this class are generally not efficiently removed and, moreover, are at increased risk for postprocedure rebound, as drug levels equilibrate across compartments.
Chemotherapy Agents
Cisplatin 48 and vincristine 49 are both highly nephrotoxic (compromising endogenous clearance) and are highly protein bound with long half-lives, lending themselves to removal via TPE. Removal will generally require multiple sessions due to significant continuing redistribution across compartments. A case report examining methotrexate removal via TPE was inconclusive due to confounding issues of measurement of serum levels only in the setting of severe renal dysfunction.
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Anticoagulants
Case reports of TPE removal of unfractionated heparin, low molecular weight heparin (dalteparin), and lepirudin (recombinant hirudin) are largely inconclusive due to failures to measure drug levels in removed plasma and failure to account for concurrent removal of coagulation factors (fibrinogen, antithrombin, and factors 2, 5, 7, 8, 9, and 10) during TPE that would mediate clinical effects in drug overdose and reversal. 28 A retrospective review on 15 TPE procedures on patients receiving continuous intravenous heparin infusion 51 showed evidence of significant heparin removal from plasma exchange; however, heparin levels were not measured in the removed plasma. Literature is limited on direct oral anticoagulants, including direct thrombin inhibitors such as dabigatran (V D 0.7 L/kg and 35% protein binding capacity) and factor 10a inhibitors such as rivaroxaban (V D <0.7 L/kg and 94% protein binding) and apixaban (V D <0.2 L/kg and 84% protein binding). PK features suggest likely removal via TPE. 29 However, the role of concurrent removal of thrombin and activated factor 10 during TPE, as well as its contribution to clinical improvement, remains to be investigated. It is also important to note that specific inhibitors for oral direct thrombin inhibitors are clinically available, while antidotes for oral factor 10a inhibitors are presently in clinical trials.
Immunosuppressive Therapies
Prednisone/prednisolone show poor removal via TPE due to moderate V D (0.6-0.7 L/kg). 12 Both tacrolimus 52 and cyclosporine 53 show high intracellular distribution, particularly within erythrocytes (50%), suggesting whatever effects TPE has on drug removal are likely mediated via incidental RBC removal. Erythrocytapheresis may have a potential clinical utility in overdose situations, but further study is required.
IVIG
Formulations of most IVIGs generally show multicompartmental kinetics (with 76% of immunoglobulin M remaining intravascular), with V D less than 0.3 L/kg. These suggest that most IVIG medications are thus susceptible to TPE removal. 54 
Monoclonal Antibody Therapies
Monoclonal antibodies such as basiliximab, 55 natalizumab, 24 and rituximab 23 tend to have long half-lives, high leukocyte specificity, intravascular protein binding, and low V D , thus allowing for significant removal via TPE. A single study 56 measured the amount of rituximab in the removed plasma and found that 47% to 54% of the drug was removed when TPE was performed 25 to 66 hours after infusion.
Pain Medications and Analgesics
Diclofenac, with greater than 99% protein binding and low V D (0.1 L/kg), is effectively removed by TPE, whereas other commonly used analgesics such as acetaminophen show poor removal due to very low protein binding (<3%) and high V D (1.0 L/kg). 57 Literature on emergent removal of opioids via TPE is absent, likely due to the existence of effective antidotes and alternative methods of reversal. Finally, despite aspirin's high protein binding (80%-90%) and low V D (0.1-0.2 L/kg), the clinical utility of removal via TPE has been unpredictable due to nonlinear PK elimination.
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Toxins and Envenomation
The 2016 ASFA guidelines suggests potential clinical utility for TPE in poisoning and snake envenomation. 26 Case series in mushroom poisoning (amanita toxins) suggest TPE can be of major clinical benefit not due to primary toxin removal but due to removal of toxic metabolites bound to albumin. 59 Studies analyzing the clinical benefits of TPE in snake bites suggest that its benefit derives from direct toxin removal and also from removal of inflammatory mediators, circulating prothrombotic immune complexes, and toxic products of hemolysis.
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Vitamins and Minerals
Only a single study was performed analyzing the effects that TPE had on vitamin levels, demonstrating reduced serum levels of vitamin B12, vitamin B6, vitamin A, vitamin C, and β-carotene following a single session of TPE. 62 Folate, thiamine, niacin (nicotinate), biotin, riboflavin, and pantothenate were unchanged. The effect of TPE on mineral levels was found in two studies. The first used membrane plasmapheresis, demonstrating reduced levels of selenium. 63 The second study studied 0.5 to 0.75 volume plasma exchanges on three children, demonstrating effective removal of copper, zinc, and selenium. 64 None of these studies measured vitamin or mineral levels in the discarded plasma bag as suggested by Ibrahim et al. 4 
Conclusions and Future Directions
It is evident that the quality and scope of current studies are insufficient to create definitive guidelines regarding which drugs may or may not be effectively removed via TPE. As such, it is imperative that the transfusion and apheresis communities continue to perform studies to better understand the impact of TPE on medication levels. We believe that such studies should be prospective in nature to examine, in a standardized way, the effects of TPE in the setting of one plasma volume exchanges, with measurements of drug levels in the patient immediately before and after the procedure, as well as drug-level measurement in the waste bag. Such studies should also include detailed information about study participants, including their age, height, weight, diagnoses, and comorbidities, such that it is clear as to what population(s) the studies would be applicable. Well-planned undertakings for commonly used drugs would significantly enhance the quality of our knowledge regarding the effects of TPE on medication levels.
PK parameters, such as protein binding affinity and V D , serve as imperfect proxies for the prediction of TPE effects on medication levels. We also need a more detailed and consistent understanding of both clinical and drug-dependent factors that interact to influence drug levels so as to be able to develop and define specific clinical guidelines for the initiation of TPE. Future avenues include expanding investigation of TPE effects in specific patient populations (eg, pediatric), examining the role of TPE in medications with large intracellular distributions (eg, tacrolimus 53 and cyclosporine 52 ), investigating the effects of TPE in entirely new classes of medication such as monoclonal antibodies, and investigating how the post-TPE milieu influences the efficacy and activity of medications.
Case Summary
Will TPE remove tacrolimus in the described 16-month-old baby boy? There are only a handful of case reports, all of which demonstrate that tacrolimus levels are relatively unaffected by TPE. 65 Tacrolimus has a large V D and is highly bound to erythrocytes; therefore, it will not be efficiently removed by TPE. The procedure was performed without incident, and no adjustments in the patient's immunosuppressive regimen were deemed necessary because of TPE. This patient was eventually discharged from the hospital in stable condition after undergoing three TPE procedures. A follow-up biopsy done approximately a month later showed persistent rejection, and a second course of TPE was trialed. The patient again tolerated the procedures well and without adjustments needed to his tacrolimus dosing.
